Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study

Authors :: Roberto Citarrella
Egle Corrado
Antonio Magán-Fernández
Angelo Maria Patti
Giuseppe Montalto
Manfredi Rizzo
Roberta Chianetta
Dragana Nikolic
Francesca Provenzano
Giuseppa Castellino
Vincenzo Provenzano
Ali A. Rizvi
Rosaria Vincenza Giglio
Patti AM, Nikolic D, Magan-Fernandez A, Giglio RV, Castellino G, Chianetta R, Citarrella R, Corrado E, Provenzano F, Provenzano V, Montalto G, Rizvi AA, Rizzo M
Source :: Diabetes research and clinical practice. 149
Publication Year :: 2018
Abstract: AIM: To evaluate the effect of exenatide long acting release (LAR) on carotid intima-media thickness (IMT) and endothelial function in patients with type 2 diabetes mellitus. METHODS: Sixty subjects with type 2 diabetes mellitus were treated with exenatide LAR as add-on to stable doses of metformin for 8 months in an open label study. Anthropometric variables, lipid profile and glycemic parameters were assessed by routine analysis. Carotid IMT by Doppler ultrasound and endothelial function by flow-mediated dilation of the brachial artery were also assessed. RESULTS: Exenatide significantly improved fasting glycaemia (from 8.8 ± 2.8 to 7.3 ± 2.2 mmol/L, p

Tools